公开(公告)号：US20230321103A1

公开(公告)日：2023-10-12

申请号：US18043419

申请日：2021-09-01

Applicant: East China University of Science and Technology

Inventor： Honglin LI ,  Zhenjiang ZHAO ,  Yanyan DIAO ,  Zhuo CHEN

IPC: A61K31/519

CPC classification number: A61K31/519

Abstract: Provided is the use of a series of pteridinones and/or a pharmaceutically acceptable salt and a prodrug thereof as a non-canonical EGFR mutant inhibitor. Specifically, the present invention relates to the use of a series of compounds as represented by formula I and a pharmaceutical composition containing the series of compounds as represented by formula I in the preparation of a drug for treating a disease containing EGFR 20insX mutation, EGFR G719X mutation and ERBB2 mutation.

公开(公告)号：US20230190713A1

公开(公告)日：2023-06-22

申请号：US17905629

申请日：2021-03-02

Applicant: EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY ,  WUHAN UNIVERSITY

Inventor： Honglin LI ,  Ke XU ,  Shiliang LI ,  Lili ZHU ,  Zhenjiang ZHAO

IPC: A61K31/426 ,  A61P31/14 ,  A61P31/16 ,  A61K31/513 ,  A61K31/427 ,  A61K31/7056 ,  A61K31/675 ,  A61K31/215 ,  A61K31/351 ,  A61K31/19 ,  A61K31/4706

CPC classification number: A61K31/426 ,  A61K31/19 ,  A61K31/215 ,  A61K31/351 ,  A61K31/427 ,  A61K31/513 ,  A61K31/675 ,  A61K31/4706 ,  A61K31/7056 ,  A61P31/14 ,  A61P31/16

Abstract: An application of a novel thiazole derivative in the treatment of an RNA virus infection and the preparation of a drug for treating an RNA virus infection. Specifically, the present invention relates to a use of a compound represented by the following formula I and a pharmaceutical composition containing a compound represented by the following formula I in treating an RNA virus infection and preparing a drug for treating a coronavirus infection.

公开(公告)号：US20180148454A1

公开(公告)日：2018-05-31

申请号：US15577518

申请日：2016-05-30

Applicant: EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY

Inventor： Honglin LI ,  Yufang XU ,  Zhenjiang ZHAO ,  Wei ZHOU ,  Yuqiong XU ,  Deheng SUN ,  Xia WANG ,  Zhuo CHEN

IPC: C07D487/04 ,  A61P35/00 ,  A61P35/02

CPC classification number: C07D487/04 ,  A61K31/519 ,  A61P35/00 ,  A61P35/02 ,  C07D475/00

Abstract: The present invention relates to a pteridinone derivative serving as an EGFR inhibitor and use thereof. Specifically, the present invention relates to a compound represented by the following formula I, pharmaceutical composition comprising the compound of the following formula I, and use of the compound in preparation of drugs for treating EGFR-mediated diseases or inhibiting EGFR.

公开(公告)号：US20230097553A1

公开(公告)日：2023-03-30

申请号：US17904587

申请日：2021-02-09

Applicant: EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY ,  WUHAN UNIVERSITY

Inventor： Honglin LI ,  Ke XU ,  Zhenjiang ZHAO

IPC: A61K31/42 ,  A61K31/277 ,  A61P31/18 ,  A61P31/16

Abstract: An application of a compound represented by formula I or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating RNA virus infection.

公开(公告)号：US20210179598A1

公开(公告)日：2021-06-17

申请号：US17046996

申请日：2019-04-12

Applicant: EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY

Inventor： Honglin LI ,  Yufang XU ,  Zhenjiang ZHAO ,  Lili ZHU

IPC: C07D413/10 ,  C07D401/14 ,  C07D405/14 ,  C07D213/73 ,  C07D401/04 ,  C07D401/10 ,  C07D487/04 ,  C07D471/04 ,  C07D401/12 ,  C07D417/04

Abstract: Provided is a selective JAK2 inhibitor and application thereof. In particular, it relates to the compound of the following Formula (I), and the use of the compound in the treatment of JAK2-mediated related diseases and in the preparation of the medicament for treating JAK2-mediated related diseases.

公开(公告)号：US20190134008A1

公开(公告)日：2019-05-09

申请号：US16306465

申请日：2017-06-02

Applicant: EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY ,  INSTITUT OF PASTEUR OF SHANGHAI, CHINESE ACADEMY OF SCIENCES

Inventor： Ke XU ,  Honglin LI ,  Yufang XU ,  Zhenjiang ZHAO ,  Lili ZHU ,  Wenlin SONG ,  Yi TONG

IPC: A61K31/426 ,  A61P31/12

Abstract: Provided are applications of a thiazole derivative in treating virus infection and in the preparation of drugs for treating virus infection. Specifically, provided are applications of a compound represented by formula (I) and a pharmaceutical composition comprising the compound represented by formula (I) in treating virus infection and in the preparation of drugs for treating virus infection:

公开(公告)号：US20220098134A1

公开(公告)日：2022-03-31

申请号：US17424105

申请日：2020-06-12

Applicant: EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY

Inventor： Honglin LI ,  Zhenjiang ZHAO ,  Rui WANG ,  Yinchu SHEN ,  Jianjun FU ,  Yufang XU ,  Xuhong QIAN ,  Qian JIAO ,  Shiliang LI

IPC: C07C33/26 ,  C07C43/23 ,  C07C49/82 ,  C07C33/30 ,  C07C69/16 ,  A61P9/12

Abstract: The present invention provides a compound as represented by formula I, or a pharmaceutically acceptable salt or ester, a prodrug, an optical isomer, a stereoisomer, or a solvate thereof. The compound provided by the present invention can be used for preparing drugs for preventing or treating hypertension, or hypertension-related diseases, or pulmonary hypertension, or pulmonary hypertension-related diseases. The compound provided by the present invention has a different mechanism from existing drugs for treating hypertension and pulmonary hypertension, thereby laying a new material foundation for the development of drugs for treating hypertension and pulmonary hypertension.

公开(公告)号：US20190290620A1

公开(公告)日：2019-09-26

申请号：US16302574

申请日：2017-05-17

Applicant: EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY

Inventor： Honglin LI ,  Zhenjiang ZHAO ,  Rui WANG ,  Yufang XU ,  Wanqi WANG ,  Yingfang YANG

IPC: A61K31/426 ,  A61P1/04

Abstract: The present invention relates to applications of a novel thiazole derivative in treating ulcerative colitis and in the preparation of drugs for treating ulcerative colitis. The present invention specifically relates to applications of a compound represented by formula I and a pharmaceutical composition containing the compound represented by formula I, in treating ulcerative colitis and in the preparation of drugs for treating ulcerative colitis:

公开(公告)号：US20210155604A1

公开(公告)日：2021-05-27

申请号：US17047002

申请日：2019-04-12

Applicant: EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY

Inventor： Honglin LI ,  Jian DING ,  Yufang XU ,  Hua XIE ,  Qiannan LI ,  Tao ZHANG ,  Zhenjiang ZHAO

IPC: C07D401/14 ,  C07D401/12 ,  C07F9/6558 ,  C07D239/94 ,  C07D403/12

Abstract: Related to a quinazoline compound serving as an EFGR triple mutation inhibitor and applications thereof. Specifically, disclosed are a compound as represented by the following formula (I), a pharmaceutical composition comprising the compound of formula (I), and applications of the compound in treating a related disease mediated by EGFR and in a medicament for treating the related disease mediated by EGFR.

公开(公告)号：US20200163983A1

公开(公告)日：2020-05-28

申请号：US16630309

申请日：2018-07-12

Applicant: EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY ,  YUNNAN UNIVERSITY ,  SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Honglin LI ,  Weilie XIAO ,  Lili ZHU ,  Lina QUAN ,  Qiao LI ,  Yanyan DIAO ,  Zhenjiang ZHAO ,  Hualiang JIANG

IPC: A61K31/704 ,  A61P35/00 ,  A61K31/56

Abstract: Provided are use of a saponin compound of formula (I) or (II), or a pharmaceutically acceptable salt, prodrug or solvate thereof, in the manufacture of a medicament targeting PD-1. The medicament targeting PD-1 is one which treats a disease by inhibiting PD-1 from binding to a ligand thereof. The disease may be a tumor, an infection caused by a bacterium, a virus or a fungus, or an inflammatory disease.